DAFTAR PUSTAKA

Adnan, Perwitasari D., & Mulyani, U. A. (2014). Reliability and Validity of St George Respiratory Questionnaire (SGRQ) into Indonesian Version. *Int J Public Health*, *3*(3), 179-184.

Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., … Yim, J. J. (2012). Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. *PLoS Medicine*, *9*(8).

Akessa, G. M., Tadesse, M., & Abebe, G. (2015). Survival analysis of loss to follow-up treatment among tuberculosis patients at Jimma University Specialized Hospital, Jimma, Southwest Ethiopia. *International Journal of Statistical Mechanics*, *2015*.

Alene, K. A., Clements, A. C., McBryde, E. S., Jaramillo, E., Lönnroth, K., Shaweno, D., ... & Viney, K. (2018). Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. *Journal of Infection*, *77*(5), 357-367.

Aung, K. J. M., Van Deun, A., Declercq, E., Sarker, M. R., Das, P. K., Hossain, M. A., & Rieder, H. L. (2014). Successful "9-month Bangladesh regimen" for multidrugresistant tuberculosis among over 500 consecutive patients. *International Journal of Tuberculosis and Lung Disease*, *18*(10), 1180–1187.

Baghaei, P., Tabarsi, P., Dorriz, D., Marjani, M., Shamaei, M., Pooramiri, M. V., ... & Velayati, A. (2011). Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. *American journal of therapeutics*, *18*(2), e29-e34.

Bastos, M. L., Lan, Z., & Menzies, D. (2017). An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. *European Respiratory Journal*, *49*(3), 1600803.

Brown, J., Capocci, S., Smith, C., Morris, S., Abubakar, I., & Lipman, M. (2015). Health status and quality of life in tuberculosis. *International Journal of Infectious Diseases*, *32*, 68-75.

Brust, J. C., Shah, N. S., Van Der Merwe, T. L., Bamber, S., Ning, Y., Heo, M., ... & Gandhi, N. R. (2013). Adverse events in an integrated, home-based

treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. *Journal of acquired immune deficiency syndromes (2013)*, *62*(4), 436.

Caminero, J. A., Cayla, J. A., García-García, J.-M., García-Pérez, F. J., Palacios, J. J., & Ruiz-Manzano, J. (2017). Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos. *Archivos de Bronconeumología*, *53*(9), 501–509.

Chahine, E. B., Karaoui, L. R., & Mansour, H. (2014). Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. *Annals of Pharmacotherapy*, *48*(1), 107-115.

Charan, J., Reljic, T., & Kumar, A. (2016). Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review. *Indian journal of pharmacology*, *48*(2), 186.

Ciza, F., Gils, T., Sawadogo, M., Decroo, T., Roggi, A., Piubello, A., & Ortuño-Gutiérrez, N. (2020). Course of adverse events during short treatment regimen in patients with rifampicin-resistant tuberculosis in Burundi. *Journal of Clinical Medicine*, *9*(6), 1873.

Collins, D., Hafidz, F., & Mustikawati, D. (2017). The economic burden of tuberculosis in Indonesia. *The International Journal of Tuberculosis and Lung Disease*, *21*(9), 1041–1048.

Datta, S., Gilman, R. H., Montoya, R., Cruz, L. Q., Valencia, T., Huff, D., ... & Evans, C. A. (2020). Quality of life, tuberculosis and treatment outcome; a case–control and nested cohort study. *European Respiratory Journal*, *56*(2).

Dheda, K., Cox, H., Esmail, A., Wasserman, S., Chang, K. C., & Lange, C. (2018). Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? *Respirology*, *23*(1), 36–45.

Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., … Warren, R. M. (2017). The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. *The Lancet Respiratory Medicine*, *5*(4), 291–360.

Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva, I., ... & Dannemann, B. (2014). Multidrug-resistant tuberculosis and culture conversion with bedaquiline. *New England Journal of Medicine*, *371*(8), 723-732.

Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). *Methods for the economic evaluation of health care programmes*. Oxford university press.

Du Toit, L. C., Pillay, V., & Danckwerts, M. P. (2006). Tuberculosis chemotherapy: current drug delivery approaches. *Respiratory research*, *7*(1), 118.

Dye, C., Scheele, S., Dolin, P., Pathania, V., & Raviglione, M. C. (1999). Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. *Jama*, *282*(7), 677-686.

Ezelarab, H. A., Abbas, S. H., Hassan, H. A., & Abuo-Rahma, G. E. D. A. (2018). Recent updates of fluoroquinolones as antibacterial agents. *Archiv der Pharmazie*, *351*(9), 1800141.

Fitzpatrick, C., Nwankwo, U., Lenk, E., de Vlas, S. J., & Bundy, D. A. (2017). An investment case for ending neglected tropical diseases. *Major Infectious Diseases. 3rd edition*.

Gerdan, V., Akkoc, N., UÇAN, E., & Kir, S. (2013). Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia. *Singapore medical journal*, *54*(6).

Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003). Fluoroquinolones, tuberculosis, and resistance. *The Lancet infectious diseases*, *3*(7), 432-442.

Gopal, P., Grüber, G., Dartois, V., & Dick, T. (2019). Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends in pharmacological sciences, 40(12), 930-940.

Gualano, G., Capone, S., Matteelli, A., & Palmieri, F. (2016). New antituberculosis drugs: from clinical trial to programmatic use. *Infectious Disease Reports*, *8*(2).

Gurung, S. C., Rai, B., Dixit, K., Worrall, E., Paudel, P. R., Dhital, R., ... & Teixeira de Siqueira-Filha, N. (2021). How to reduce household costs for people with tuberculosis: a longitudinal costing survey in Nepal. Health Policy and Planning, 36(5), 594-605.

Gutierrez, M. G., Master, S. S., Singh, S. B., Taylor, G. A., Colombo, M. I., & Deretic, V. (2004). Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. *Cell*, *119*(6), 753-766.

Harouna, S. H., Ortuno-Gutierrez, N., Souleymane, M. B., Kizito, W., Morou, S., Boukary, I., ... & Piubello, A. (2019). Short-course treatment outcomes and

adverse events in adults and children-adolescents with MDR-TB in Niger. *The International Journal of Tuberculosis and Lung Disease*, *23*(5), 625-630.

Hendrik, H., Perwitasari, D. A., Mulyani, U. A., & Thobari, J. A. (2017). Pengukuran kualitas hidup pasien tuberkulosis menggunakan instrumen st george respiratory questionnaire (sgrq) di yogyakarta. *Jurnal Ilmu Farmasi dan Farmasi Klinik*, 28-34.

Ionescu, A. M., Mpobela Agnarson, A., Kambili, C., Metz, L., Kfoury, J., Wang, S., ... & Thomas, A. (2018). Bedaquiline-versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. *Expert Review of Pharmacoeconomics & Outcomes Research*, *18*(6), 677-689.

Jaber, A. A. S., & Ibrahim, B. (2019). Health-related quality of life of patients with multidrug-resistant tuberculosis in Yemen: prospective study. *Health and quality of life outcomes*, *17*(1), 1-14.

Jilani, T. N., Avula, A., Gondal, Z., & Siddiqui, A. H. (2018). Active tuberculosis. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2022. PMID: 30020618.

Kaplan, R. M., & Hays, R. D. (2022). Health-related quality of life measurement in public health. *Annual review of public health*, *43*, 355-373.

Karimi, M., & Brazier, J. (2016). Health, health-related quality of life, and quality of life: what is the difference?. *Pharmacoeconomics*, *34*(7), 645-649.

Kaushik, A., Ammerman, N. C., Tyagi, S., Saini, V., Vervoort, I., Lachau-Durand, S., ... & Andries, K. (2019). Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection. *Antimicrobial agents and chemotherapy*, *63*(4), e00007-19.

Kelly MP, Bonnefoy J, Morgan A, Florenza A. (2006). The development of the evidence base about the social determinants of health. *World Health Organization Commission on Social Determinants of Health—Measurement and Evidence Knowledge Network*.

Kementerian Kesehatan Republik Indonesia. (2016). Pedoman Nasional Penanggulangan Tuberkulosis Tahun 2016.

Kementerian Kesehatan RI. (2015). *Buku Saku Pasien TB MDR*. https://doi.org/db06-1464 [pii]\r10.2337/db06-1464

Kementerian kesehatan RI. (2011). Rencana aksi nasional programmatic management of drug resistance Pengendalian Tuberkulosis, 54.

Kim, J. H., Kwon, O. J., Kim, Y. S., Park, M. S., Hwang, S., & Shim, T. S. (2020). Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation. *Respiratory Investigation*, *58*(1), 45-51.

Krause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016). Aminoglycosides: an overview. Cold Spring Harbor perspectives in medicine, 6(6), a027029.Kuaban, C., Noeske, J., Rieder, H. L., Aït-Khaled, N., Abena Foe, J. L., & Trébucq, A. (2015). High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. *The International Journal of Tuberculosis and Lung Disease*, *19*(5), 517–524.

Lambert, N., Abdalla, A. E., Duan, X., & Xie, J. (2017). Emerging drugs and drug targets against tuberculosis. *Journal of Drug Targeting*, *25*(4), 296–306.

Lan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Brode, S. K., ... & Menzies, D. (2020). Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet Respiratory Medicine, 8(4), 383-394.

Lee, J. Y. (2015). Diagnosis and treatment of extrapulmonary tuberculosis. *Tuberculosis and Respiratory Diseases*, *78*(2), 47–55.

Lipsky, B. A., & Baker, C. A. (1999). Fluoroquinolone toxicity profiles: a review focusing on newer agents. *Clinical Infectious Diseases*, *28*(2), 352-361.

Lu, X., Smare, C., Kambili, C., El Khoury, A. C., & Wolfson, L. J. (2017). Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. BMC health services research, 17(1), 1-12.

Mahajan, R. (2013). Bedaquiline: first FDA-approved tuberculosis drug in 40 years. *International Journal of Applied and Basic Medical Research*, *3*(1), 1-2.

Mangunnegoro, H., & Hudoyo, A. (1999). Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia. *Chemotherapy*, *45*(Suppl. 2), 19-25.

Madan, J. J., Rosu, L., Tefera, M. G., van Rensburg, C., Evans, D., Langley, I., ... & Squire, S. B. (2020). Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial. Bulletin of the World Health Organization, 98(5), 306.

Massud, A., Sulaiman, S. A. S., Ahmad, N., Shafqat, M., Ming, L. C., & Khan, A. H. (2022). Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study. *Frontiers in Pharmacology*, *13*.

Mirnejad, R., Asadi, A., Khoshnood, S., Mirzaei, H., Heidary, M., Fattorini, L., ... & Darban-Sarokhalil, D. (2018). Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomedicine & Pharmacotherapy, 105, 1353-1359.

Mesic, A., Khan, W. H., Lenglet, A., Lynen, L., Ishaq, S., Phyu, E. H. H., ... & Decroo, T. (2020). Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study. *Plos one*, *15*(8), e0237787.

Migliori, G. B., Espinal, M., Danilova, I. D., Punga, V. V, Grzemska, M., & Raviglione, M. C. (2002). Frequency of recurrence among MDR-tB cases "successfully" treated with standardised short-course chemotherapy. *The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union against Tuberculosis and Lung Disease*, *6*(10), 858–864. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12365571

Moyo, S., Cox, H. S., Hughes, J., Daniels, J., Synman, L., De Azevedo, V., ... & Van Cutsem, G. (2015). Loss from treatment for drug resistant tuberculosis: risk factors and patient outcomes in a community-based program in Khayelitsha, South Africa. *PloS one*, *10*(3), e0118919.

Mnyambwa, N. P., Kim, D. J., Ngadaya, E. S., Kazwala, R., Petrucka, P., & Mfinanga, S. G. (2017). Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis. *European Journal of Clinical Microbiology & Infectious Diseases*, *36*(11), 2021-2028.

Nasution, H. S., & Wahyono, T. Y. M. (2020). Faktor-Faktor Yang Mempengaruhi Kejadian Putus Berobat Pada Kasus Tb MDR/RR Di Dki Jakarta Tahun 2014-2015. *Jurnal Kesmas Jambi*, *4*(2), 50-58.

Nilamsari, W. P., Rizqi, M. F., Regina, N. O., Wulaningrum, P. A., & Fatmawati, U. (2021). Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study. *Journal of Basic and Clinical Physiology and Pharmacology*, *32*(4), 783-787.

Nunn, A. J., Rusen, I. D., Van Deun, A., Torrea, G., Phillips, P. P. J., Chiang, C.-Y.,Meredith, S. K. (2014). Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. *Trials*, *15*, 353.

Pantoja, A., Floyd, K., Unnikrishnan, K. P., Jitendra, R., Padma, M. R., Lal, S. S., ... & Lönnroth, K. (2009). Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. *The International journal of tuberculosis and lung disease*, *13*(6), 698-704.

Pham P-CT, Pham P-AT, Pham SV, Pham P-TT, Pham P-MT, Pham P-TT. Hypomagnesemia: a clinical perspective. Int J Nephrol Renovascular Dis 2014;7:219

Piatek, A. S., Van Cleeff, M., Alexander, H., Coggin, W. L., Rehr, M., Van Kampen, S., & Mukadi, Y. (2013). GeneXpert for TB diagnosis: planned and purposeful implementation. *Global health: science and Practice*, *1*(1), 18-23.

Piubello, A., Harouna, S. H., Souleymane, M. B., Boukary, I., Morou, S., Daouda, M., … Van Deun, A. (2014). High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. *The International Journal of Tuberculosis and Lung Disease*, *18*(10), 1188–1194.

Rai, M., & Goyal, R. (2018). Pharmacoeconomics in healthcare. In Pharmaceutical medicine and translational clinical research (pp. 465-472). Academic Press.

Robinson, S., & Giffin, R. (Eds.). (2010). *Addressing the threat of drug-resistant tuberculosis: a realistic assessment of the challenge: workshop summary*. National Academies Press.

Ruslami, R., Ganiem, A. R., Dian, S., Apriani, L., Achmad, T. H., van der Ven, A. J., ... & van Crevel, R. (2013). Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. *The Lancet Infectious Diseases*, *13*(1), 27-35.

Saeedi, M., & Hajoj, S. (2017). Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis. *Infection and drug resistance*, *10*, 333.

Samuels, J. P., Sood, A., Campbell, J. R., Ahmad Khan, F., & Johnston, J. C. (2018). Comorbidities and treatment outcomes in multidrug resistant tuberculosis: A systematic review and meta-analysis. *Scientific Reports*, *8*(1), 1–13.

Sanchez, L. . 2005. Pharmacoeconomics: Principles, Methods, And Applications. In DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey,L.M. (Ed.), Pharmacothrapy: A Pathophysiologic Approach (6th ed., pp. 1–9).McGraw-Hill Company Inc.

Santos, M., Monteiro, A. L., Biz, A. N., Guerra, A., Cramer, H., Canuto, V., ... & Zimmermann, I. (2022). Guidelines for Utility Measurement for Economic Analysis: The Brazilian Policy. Value in Health Regional Issues, 31, 67-73.

Schnippel, K., Rosen, S., Shearer, K., Martinson, N., Long, L., Sanne, I., & Variava, E. (2013). Costs of inpatient treatment for multi-drug-resistant tuberculosis in S outh A frica. *Tropical Medicine & International Health*, *18*(1), 109-116.

Seung, K. J., Keshavjee, S., & Rich, M. L. (2015). Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. *Cold Spring Harbor Perspectives in Medicine*, *5*(9), a017863.

Seaworth, B. J., & Griffith, D. E. (2017). Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. *Microbiology Spectrum*, *5*(2). https://doi.org/10.1128/microbiolspec.TNMI7-0042-2017

Sharma R, Yadav R, Sharma M, Saini V, Koushal V (2014). Quality of Life of MULTI-DRUG Resistant Tuberculosis Patients: a Study of North India. *Acta Medica*, 52(6):448–453.

Sharma, D., Dhuriya, Y. K., Deo, N., & Bisht, D. (2017). Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis. *Frontiers in Microbiology*, *8*, 2452.

Shi, R., Itagaki, N., & Sugawara, I. (2007). Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. *Mini reviews in medicinal chemistry*, *7*(11), 1177-1185.

Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020). Recent updates on drug resistance in Mycobacterium tuberculosis. *Journal of applied microbiology*, *128*(6), 1547-1567.

Soedarsono, S., Mertaniasih, N. M., Kusmiati, T., Permatasari, A., Juliasih, N. N., Hadi, C., & Alfian, I. N. (2021). Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects. *BMC Pulmonary Medicine*, *21*(1), 1-8.

Soeroto, A. Y., Pratiwi, C., Santoso, P., & Lestari, B. W. (2021). Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. *PLoS One*, *16*(2), e0246284.

Suparyatmo, B. Rina AS, H. Harsini, and S. Sukma, "Potassium in multidrug resistance tuberculosis with kanamycin," *Indonesian Journal of Clinical Pathology and Medical Laboratory*, vol. 21, no. 1, pp. 16–19, 2016.

Svensson, E. M., Dosne, A. G., & Karlsson, M. O. (2016). Population pharmacokinetics of bedaquiline and metabolite M2 in patients with drug-resistant tuberculosis: the effect of time-varying weight and albumin. *CPT: pharmacometrics & systems pharmacology*, *5*(12), 682-691.

Thomas, B. E., Shanmugam, P., Malaisamy, M., Ovung, S., Suresh, C., Subbaraman, R., … Nagarajan, K. (2016). Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: A Systematic Review. *PLOS ONE*, *11*(1), e0147397.

Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharmacy Practice (Granada), 19(1).

Trébucq, A., Decroo, T., Van Deun, A., Piubello, A., Chiang, C. Y., Koura, K. G., & Schwoebel, V. (2019). Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence. *Journal of clinical medicine*, *9*(1), 55.

Trubnikov, A., Hovhannesyan, A., Akopyan, K., Ciobanu, A., Sadirova, D., Kalandarova, L., ... & Gadoev, J. (2021). Effectiveness and safety of a shorter treatment regimen in a setting with a high burden of multidrug-resistant tuberculosis. *International journal of environmental research and public health*, *18*(8), 4121.

Tsuyuguchi, K., Sasaki, Y., Mitarai, S., Kurosawa, K., Saito, Y., & Koh, T. (2019). Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: an interim analysis of an open-label, phase 2 study. *Respiratory Investigation*, *57*(4), 345-353.

Van den Hof, S., Collins, D., Hafidz, F., Beyene, D., Tursynbayeva, A., & Tiemersma, E. (2016). The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan. *BMC Infectious Diseases*, *16*(1), 470.

Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010). Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis. *American Journal of Respiratory and Critical Care Medicine*, *182*(5), 684–692.

Van Deun, A., Decroo, T., Piubello, A., de Jong, B. C., Lynen, L., & Rieder, H. L. (2018). Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. *The International Journal of Tuberculosis and Lung Disease*, *22*(3), 239–245.

Veesa, K. S., John, K. R., Moonan, P. K., Kaliappan, S. P., Manjunath, K., Sagili, K. D., ... & Minz, S. (2018). Diagnostic pathways and direct medical costs incurred by new adult pulmonary tuberculosis patients prior to anti-tuberculosis treatment–Tamil Nadu, India. PLoS One, 13(2), e0191591.

Walley, T. (2004). Pharmacoeconomics for migraine and headache researchers: basic concepts, methods and terminology. *The Journal of Headache and Pain*, *5*(4), 217-223.

Wirth, D., Dass, R., & Hettle, R. (2017). Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. *BMC health services research*, *17*(1), 1-11.

World Health Organization. (2011). An International Roadmap for Tuberculosis: Towards a world free of tuberculosis. *Geneva Switzerland*, 1–80.

World Health Organization. (2012). *Programme on mental health: WHOQOL user manual* (No. WHO/HIS/HSI Rev. 2012.03). World Health Organization.

World Health Organization. (2014). Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis.

World Health Organization. (2015). Global Action Framework for TB Research. Geneva: World Health Organization (2015). *Global Action Framework for TB Research. Geneva: World Health Organization; 2015.*

World Health Organization. (2016). WHO treatment guidelines for drug-resistant tuberculosis. *World Health Organisation*.

World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization (2017). *Global tuberculosis report 2017. Geneva: World Health Organization; 2017.*

World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization (2018). *Global tuberculosis report 2018. Geneva: World Health Organization; 2018.* .

Zhang, Y., & Yew, W. W. (2009). Mechanisms of drug resistance in Mycobacterium tuberculosis [State of the art series. Drug-resistant tuberculosis. Edited by CY. Chiang. Number 1 in the series]. *The International Journal of Tuberculosis and Lung Disease*, *13*(11), 1320-1330.